Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024

Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. The company's management will present and engage in one-on-one investor meetings during the event.

Key details of the virtual conference include:

• Presentation available on August 15, 2024, at 7:00 am ET
• Presenter: Frederic Guerard, PharmD, CEO of Opthea
• Webcast accessible via a provided link and on Opthea's website

This participation highlights Opthea's ongoing efforts to engage with investors and showcase its progress in developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD).

MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4^th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024.

Virtual Conference Details:

Presentation: Available on Thursday, August 15, 2024, 7:00 am ET

Presenter: Frederic Guerard, PharmD, CEO Opthea

The webcast will be accessible both via the link: https://journey.ct.events/view/bc8c5e95-651e-4824-bee8-923a1a7479fa and on the “Events & Presentations” section of Opthea’s website at http://ir.opthea.com/.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, CEO

Investor Inquiries

PJ Kelleher 
LifeSci Advisors, LLC 
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579 

Media Inquiries 

Silvana Guerci-Lena 
NorthStream Global Partners 
Email: silvana@nsgpllc.com 

Join our email database to receive program updates:  
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com   

Source: Opthea Limited

FAQ

When is Opthea (OPT) presenting at the H.C. Wainwright Ophthalmology Virtual Conference?

Opthea (OPT) is presenting at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024, with the presentation available from 7:00 am ET.

Who will be presenting for Opthea (OPT) at the virtual conference?

Frederic Guerard, PharmD, CEO of Opthea, will be presenting for the company at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.

How can investors access Opthea's (OPT) presentation at the virtual conference?

Investors can access Opthea's presentation via a provided webcast link or through the 'Events & Presentations' section of Opthea's website at http://ir.opthea.com/.

What is the main focus of Opthea's (OPT) clinical research?

Opthea (OPT) is focused on developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD).